Compare LMAT & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LMAT | VCEL |
|---|---|---|
| Founded | 1983 | 1989 |
| Country | | US |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.0B |
| IPO Year | N/A | 1996 |
| Metric | LMAT | VCEL |
|---|---|---|
| Price | $90.71 | $37.36 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | ★ $101.83 | $57.50 |
| AVG Volume (30 Days) | 95.9K | ★ 362.4K |
| Earning Date | 01-01-0001 | 04-03-2026 |
| Dividend Yield | ★ 0.88% | N/A |
| EPS Growth | N/A | ★ 385.71 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $237,224,000.00 |
| Revenue This Year | $15.17 | $18.02 |
| Revenue Next Year | $9.07 | $18.52 |
| P/E Ratio | ★ $39.12 | $151.69 |
| Revenue Growth | N/A | ★ 20.10 |
| 52 Week Low | $71.42 | $29.24 |
| 52 Week High | $105.55 | $55.41 |
| Indicator | LMAT | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 65.77 | 53.53 |
| Support Level | $85.78 | $33.30 |
| Resistance Level | $88.50 | $36.56 |
| Average True Range (ATR) | 2.24 | 1.61 |
| MACD | 0.33 | 0.09 |
| Stochastic Oscillator | 100.00 | 88.18 |
LeMaitre Vascular Inc manufactures and distributes medical devices for the treatment of peripheral vascular disease. Its products are used during open vascular surgery and address several anatomical areas, such as the carotid, lower extremities, upper extremities, and aorta. The firm's lower extremities product line contributes towards the proportion of revenue, followed by the carotid product line. LeMaitre's surgical devices include angioscopes, balloon catheters, carotid shunts, phlebectomy devices, vascular grafts, vascular patches and vessel closure systems.It has a single operating segment engaged in the development, manufacturing, and marketing of medical devices and implants, as well as the processing and cryopreservation of human tissues for implantation in patients.
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.